The impact of platelet-rich plasma injection on anterior cruciate ligament reconstruction: a systematic review and meta-analysis.

IF 4.8 3区 工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Frontiers in Bioengineering and Biotechnology Pub Date : 2025-10-01 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1625271
Yiran Zhang, Zhikang Xiao, Zhe Fan, Yingxin Zhang, Jianzhong Xu, Kun Wang
{"title":"The impact of platelet-rich plasma injection on anterior cruciate ligament reconstruction: a systematic review and meta-analysis.","authors":"Yiran Zhang, Zhikang Xiao, Zhe Fan, Yingxin Zhang, Jianzhong Xu, Kun Wang","doi":"10.3389/fbioe.2025.1625271","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review and meta-analysis evaluates platelet-rich plasma (PRP) efficacy in anterior cruciate ligament reconstruction (ACLR) through 15-year Randomized controlled trials (RCTs) data, focusing on postoperative recovery, rehabilitation acceleration, and functional outcomes optimization.</p><p><strong>Methods: </strong>We conducted an extensive systematic search in PubMed, Embase, and Web of Science to find relevant studies on using PRP in ACLR. Randomized controlled trials analyzing the comparative effectiveness of PRP compared to control interventions in individuals undergoing ACLR were systematically identified. The focus was on studies that provided reliable outcome measures, encompassing validated clinical assessments and objective imaging results. Outcome indicators included the Visual Analog Scale (VAS) for pain perception, the International Knee Documentation Committee (IKDC) score, Lysholm score, Tegner activity scale, KT-1000 side-to-side difference, graft characteristics, and associated complications. Additionally, subgroup analyses were categorized based on evaluation timelines, distinguishing between preoperative and postoperative assessments.</p><p><strong>Results: </strong>This meta-analysis of 24 studies demonstrated time-dependent effects of PRP supplementation following ACLR. The PRP group exhibited significant improvement in IKDC scores at 12 months post-operatively (mean difference: 2.09, P = 0.01, I<sup>2</sup> = 23%), while Lysholm scores showed significant enhancement at 6 months (mean difference: 3.33, P = 0.03, I<sup>2</sup> = 58%). Pain reduction, assessed by VAS scores, was significantly greater in the PRP group at 3 months (mean difference: -1.33, P < 0.01, I<sup>2</sup> = 38%) with borderline significance at 6 months (mean difference: -0.78, P = 0.05). Notably, PRP intervention significantly reduced anterior tibial translation compared to controls (mean difference: -1.34 mm, 95% CI: -1.56 to -1.13, P < 0.01, I<sup>2</sup> = 73%), indicating improved knee stability. Pre-operative KT-1000 measurements suggested a trend toward reduced knee laxity in the PRP group (mean difference: -0.70 mm, 95% CI: -1.45 to 0.05, P = 0.07), though this effect did not persist post-operatively. No significant between-group differences were observed in Tegner activity scores, Signal-to-Noise Quotient, or Pivot Shift Test results at any follow-up interval.</p><p><strong>Conclusion: </strong>This meta-analysis indicates that PRP application during and shortly after ACLR offers limited clinical benefits. Although there is notable short-term pain relief, long-term efficacy remains unclear, with improvements not meeting minimal clinically important differences (MCID) and no significant changes in knee stability or graft maturation. Further research is needed to establish optimal PRP protocols and standardization for ACLR.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1625271"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1625271","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This systematic review and meta-analysis evaluates platelet-rich plasma (PRP) efficacy in anterior cruciate ligament reconstruction (ACLR) through 15-year Randomized controlled trials (RCTs) data, focusing on postoperative recovery, rehabilitation acceleration, and functional outcomes optimization.

Methods: We conducted an extensive systematic search in PubMed, Embase, and Web of Science to find relevant studies on using PRP in ACLR. Randomized controlled trials analyzing the comparative effectiveness of PRP compared to control interventions in individuals undergoing ACLR were systematically identified. The focus was on studies that provided reliable outcome measures, encompassing validated clinical assessments and objective imaging results. Outcome indicators included the Visual Analog Scale (VAS) for pain perception, the International Knee Documentation Committee (IKDC) score, Lysholm score, Tegner activity scale, KT-1000 side-to-side difference, graft characteristics, and associated complications. Additionally, subgroup analyses were categorized based on evaluation timelines, distinguishing between preoperative and postoperative assessments.

Results: This meta-analysis of 24 studies demonstrated time-dependent effects of PRP supplementation following ACLR. The PRP group exhibited significant improvement in IKDC scores at 12 months post-operatively (mean difference: 2.09, P = 0.01, I2 = 23%), while Lysholm scores showed significant enhancement at 6 months (mean difference: 3.33, P = 0.03, I2 = 58%). Pain reduction, assessed by VAS scores, was significantly greater in the PRP group at 3 months (mean difference: -1.33, P < 0.01, I2 = 38%) with borderline significance at 6 months (mean difference: -0.78, P = 0.05). Notably, PRP intervention significantly reduced anterior tibial translation compared to controls (mean difference: -1.34 mm, 95% CI: -1.56 to -1.13, P < 0.01, I2 = 73%), indicating improved knee stability. Pre-operative KT-1000 measurements suggested a trend toward reduced knee laxity in the PRP group (mean difference: -0.70 mm, 95% CI: -1.45 to 0.05, P = 0.07), though this effect did not persist post-operatively. No significant between-group differences were observed in Tegner activity scores, Signal-to-Noise Quotient, or Pivot Shift Test results at any follow-up interval.

Conclusion: This meta-analysis indicates that PRP application during and shortly after ACLR offers limited clinical benefits. Although there is notable short-term pain relief, long-term efficacy remains unclear, with improvements not meeting minimal clinically important differences (MCID) and no significant changes in knee stability or graft maturation. Further research is needed to establish optimal PRP protocols and standardization for ACLR.

Abstract Image

Abstract Image

Abstract Image

富血小板血浆注射对前交叉韧带重建的影响:一项系统回顾和荟萃分析。
目的:本系统综述和荟萃分析通过15年的随机对照试验(rct)数据评估富血小板血浆(PRP)在前交叉韧带重建(ACLR)中的疗效,重点关注术后恢复、康复加速和功能结果优化。方法:我们在PubMed、Embase和Web of Science中进行了广泛的系统检索,找到了在ACLR中使用PRP的相关研究。系统地确定了随机对照试验,分析PRP与对照干预在ACLR患者中的比较效果。重点是提供可靠结果测量的研究,包括经过验证的临床评估和客观影像学结果。结果指标包括疼痛感知的视觉模拟量表(VAS)、国际膝关节文献委员会(IKDC)评分、Lysholm评分、Tegner活动量表、KT-1000侧差、移植物特征和相关并发症。此外,根据评估时间表对亚组分析进行分类,区分术前和术后评估。结果:这项对24项研究的荟萃分析证明了ACLR后补充PRP的时间依赖性效果。PRP组术后12个月IKDC评分有显著改善(平均差异为2.09,P = 0.01, I2 = 23%),术后6个月Lysholm评分有显著改善(平均差异为3.33,P = 0.03, I2 = 58%)。VAS评分显示,PRP组疼痛减轻程度在3个月时显著高于对照组(平均差异:-1.33,P < 0.01, I2 = 38%), 6个月时显著低于对照组(平均差异:-0.78,P = 0.05)。值得注意的是,与对照组相比,PRP干预显著减少了胫骨前移位(平均差异:-1.34 mm, 95% CI: -1.56至-1.13,P < 0.01, I2 = 73%),表明膝关节稳定性得到改善。术前KT-1000测量显示PRP组有膝关节松弛程度降低的趋势(平均差异:-0.70 mm, 95% CI: -1.45至0.05,P = 0.07),尽管这种影响在术后不持续。在任何随访期间,Tegner活动评分、信噪比或枢轴移位测试结果均未观察到组间显著差异。结论:本荟萃分析表明,在ACLR期间和之后不久应用PRP可提供有限的临床益处。虽然有显著的短期疼痛缓解,但长期疗效尚不清楚,改善未达到最小临床重要差异(MCID),膝关节稳定性或移植物成熟无显著变化。建立ACLR的最佳PRP协议和标准化需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Bioengineering and Biotechnology
Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering
CiteScore
8.30
自引率
5.30%
发文量
2270
审稿时长
12 weeks
期刊介绍: The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信